Company WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 20/06/2025			5-day change	1st Jan Change
65.27 ^CNY	+0.52%		-4.39%	+18.59%

18/06	US-China Tensions Cause Delay in Chinese Drug Research Projects, Sources Say	MT
18/06	China pharma projects disrupted by Sino-US tensions	RE

Business description: WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:

- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;

- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;

- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;

- other (0.1%).

Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Number of employees: 39,414

Sales by Activity: WuXi AppTec Co., Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024
Chemical Business	-	1.41TCr	2.88TCr	2.92TCr	2.91TCr
Test Business	-	452.51Cr	571.87Cr	653.97Cr	567.07Cr
Biology Business	-	198.51Cr	247.51Cr	255.26Cr	254.39Cr
High-end therapy CTDMO business (Wu Xi ATU)	-	102.64Cr	130.8Cr	130.96Cr	-
Clinical Research and Other CRO Services	116.89Cr	-	-	-	-
US District Laboratory Services	151.66Cr	-	-	-	-
Laboratory Services in China	854.58Cr	-	-	-	-
Unallocated Other	2.21Cr	2.75Cr	3.36Cr	4.1Cr	65Cr
Domestic New Drug Research and Development Service Unit (Wu Xi DDSU)	528.21Cr	125.1Cr	97Cr	73Cr	-

See all business segments

Geographical breakdown of sales: WuXi AppTec Co., Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024
Overseas	-	-	-	3.3TCr	3.09TCr
China	414.53Cr	580.2Cr	752.6Cr	733.05Cr	704.76Cr
Asia	68Cr	-	-	-	-
Rest of World	20Cr	123.4Cr	151.2Cr	-	-
Europe	265.08Cr	371.9Cr	443.2Cr	-	-
United States	886.19Cr	1.21TCr	2.59TCr	-	-

See all geographic segments

Executive Committee: WuXi AppTec Co., Ltd.

Manager	Title	Age	Since
Zhao Hui Zhang LAW	General Counsel	55	01/12/2000
Ge Li CEO	Chief Executive Officer	57	06/06/2023
Qing Yang CEO	Chief Executive Officer	56	21/05/2020
Min Zhang Chen CEO	Chief Executive Officer	55	02/08/2021
Florence Shi DFI	Director of Finance/CFO	51	01/01/2022

See WUXI APPTEC CO., LTD. governance

Composition of the Board of Directors: WuXi AppTec Co., Ltd.

Director	Title	Age	Since
Edward Hu BRD	Director/Board Member	62	23/03/2016
Ge Li CHM	Chairman	57	01/12/2000
Zhao Hui Zhang BRD	Director/Board Member	55	01/12/2000
Min Zhang Chen BRD	Director/Board Member	55	06/05/2022
Harry He CHM	Chairman	59	15/07/2016
Min Fang Zhu BRD	Director/Board Member	54	11/03/2016
Xiao Meng Tong BRD	Director/Board Member	51	23/03/2016
Qing Yang BRD	Director/Board Member	56	15/05/2020
Bo Yang Wu BRD	Director/Board Member	61	31/08/2020
Yi Bing Wu BRD	Director/Board Member	56	23/03/2016

Composition of the Board of Directors

Shareholders: WuXi AppTec Co., Ltd.

Name	Equities	%	Valuation
Ge Li 23.19 %	59,34,58,536	23.19 %	5 238 M ¥
Temasek Holdings Pte Ltd. (Investment Management) 4.492 %	11,49,82,796	4.492 %	1 015 M ¥
Shanghai Zhongmin Yinfu Capital Management Co. Ltd. 3.402 %	8,70,74,568	3.402 %	769 M ¥
Summer Bloom Investments (I) Pte Ltd. 3.313 %	8,47,92,526	3.313 %	748 M ¥
China Asset Management Co., Ltd. 2.868 %	7,34,07,724	2.868 %	648 M ¥

Name	Equities	%	Valuation
Qatar Holding LLC 9.868 %	3,81,98,400	9.868 %	335 M ¥
Fidelity Management & Research Co. LLC 6.602 %	2,55,53,151	6.602 %	224 M ¥
Invesco Advisers, Inc. 5.056 %	1,95,71,608	5.056 %	172 M ¥
Schroder Investment Management (Hong Kong) Ltd. 4.259 %	1,64,85,600	4.259 %	145 M ¥
FIAM LLC 3.129 %	1,21,12,719	3.129 %	106 M ¥

List of WUXI APPTEC CO., LTD. shareholders

Holdings: WuXi AppTec Co., Ltd.

Name	Equities	%	Valuation
WUXI XDC CAYMAN INC. 21.91%	26,32,00,000	21.91%	1,34,09,14,512 $
SENSORION 1.75%	52,49,608	1.75%	23,95,764 $

Company details: WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd.

288 Fute Middle Road Waigaoqiao Free Trade Zone

200131, Shanghai

+86 21 5046 1111

http://www.wuxiapptec.com.cn

Group companies: WuXi AppTec Co., Ltd.

Name	Category and Sector
STA Pharmaceutical Hong Kong Ltd. STA Pharmaceutical Hong Kong Ltd. Pharmaceuticals: MajorHealth Technology Part of New Wuxi Life Science Holdings Ltd., STA Pharmaceutical Hong Kong Ltd. is a pharmaceutical manufacturing company. The company is based in Hong Kong, Hong Kong.	Pharmaceuticals: Major

See all subsidiaries

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
WUXI APPTEC CO., LTD.	+0.52%	-4.39%	+61.20%	-30.38%	2.61TCr
REGENERON PHARMACEUTICALS, INC.	-0.75%	-3.69%	-51.60%	-13.14%	5.39TCr
ARGENX SE	-0.44%	-6.27%	+26.71%	+39.09%	3.32TCr
BIONTECH SE	+2.04%	-0.04%	+25.86%	-13.85%	2.62TCr
INSMED INCORPORATED	+3.24%	+4.00%	+51.02%	+427.38%	1.95TCr
SUMMIT THERAPEUTICS INC.	+1.98%	+3.94%	+159.27%	+1,803.70%	1.53TCr
GENMAB A/S	-1.78%	-7.02%	-23.75%	-35.98%	1.31TCr
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	-13.93%	+107.76%	-65.12%	1.25TCr
EXELIXIS, INC.	-0.91%	-2.93%	+81.85%	+99.95%	1.1TCr
AKESO, INC.	-0.81%	-4.75%	+156.10%	+312.19%	1.04TCr
Average	+0.31%	-3.53%	+59.44%	+252.38%	2.21TCr
Weighted average by Cap.	+0.29%	-3.34%	+33.34%	+173.59%